中国药业2023，Vol.32Issue(24)：5-8,4.DOI:10.3969/j.issn.1006-4931.2023.24.002
我国特药药房执业药师作用发挥路径探索
Path Exploration on How Licensed Pharmacists Playing the Role in Specialty Pharmacies in China
摘要
Abstract
Objective To provide a reference for playing the role of licensed pharmacists and ensuring the rational use of drugs for specialty diseases.Methods The current status of the development of specialty pharmacies in China was summarized,the work development of licensed pharmacists in specialty pharmacies in the United States was analyzed,and the paths to play the role of licensed pharmacists in specialty pharmacies in China and ensure the safe and rational use of specialty drugs by the public were explored.Results China's specialty pharmacies were still in their infancy,but the development environment and momentum was good.Up to July 2021,there were over 1 400 professional pharmacies retailing new specialty drugs mainly for tumors,viruses and autoimmune diseas in China.The management of specialty pharmacies in the United States was standardized,a specialty drug management mode of multi-departmental coordination and mutual supervision had been formed,and licensed pharmacists carried out medication treatment management service and comprehensive guidance on diet,life and emotion with patients as the center.Conclusion It is suggested that licensed pharmacists in specialty pharmacies in China should strengthen the supervision and management of specialty drugs to ensure the quality safety of specialty drugs,explore and carry out medication treatment management service to improve the efficacy of specialty drugs,participate in specialty drug professional knowledge training to continuously improve professionalism and practice ability and ensure the patients' medication safety.关键词
特药药房/执业药师/治疗特殊疾病药品/药物治疗管理服务/合理用药/药学服务Key words
specialty pharmacy/licensed pharmacist/drugs for specialty diseases/medication treatment management service/rational drug use/pharmaceutical care分类
医药卫生引用本文复制引用
李朝辉,周玥,张婷婷..我国特药药房执业药师作用发挥路径探索[J].中国药业,2023,32(24):5-8,4.基金项目
国家药品监督管理局委托课题[NMPA2020]. （）
